Apellis Pharmaceuticals, Inc.
APLS
$19.42
$0.633.35%
| Weiss Ratings | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.96 | |||
| Price History | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.57% | |||
| 30-Day Total Return | -22.78% | |||
| 60-Day Total Return | -33.10% | |||
| 90-Day Total Return | -42.76% | |||
| Year to Date Total Return | -41.44% | |||
| 1-Year Total Return | -65.15% | |||
| 2-Year Total Return | -75.62% | |||
| 3-Year Total Return | -63.65% | |||
| 5-Year Total Return | -30.91% | |||
| 52-Week High % Change | -67.52% | |||
| 52-Week Low % Change | 7.46% | |||
| Price | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $57.85 | |||
| 52-Week Low Price | $17.49 | |||
| 52-Week Low Price (Date) | Apr 10, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.36B | |||
| Enterprise Value | 2.41B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.60 | |||
| Earnings Per Share Growth | -64.32% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.99 | |||
| Price/Book (Q) | 10.24 | |||
| Enterprise Value/Revenue (TTM) | 3.09 | |||
| Price | $19.42 | |||
| Enterprise Value/EBITDA (TTM) | -14.78 | |||
| Enterprise Value/EBIT | -14.62 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 124.52M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 977 5700 | |||
| Address | 100 Fifth Avenue Waltham, MA 02451 | |||
| Website | apellis.com | |||
| Country | United States | |||
| Year Founded | 2009 | |||
| Profitability | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -21.11% | |||
| Profit Margin | -25.32% | |||
| Management Effectiveness | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.32% | |||
| Return on Equity | -- | |||
| Income Statement | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 781.37M | |||
| Total Revenue (TTM) | 781.37M | |||
| Revenue Per Share | $6.27 | |||
| Gross Profit (TTM) | 336.08M | |||
| EBITDA (TTM) | -163.18M | |||
| EBIT (TTM) | -164.98M | |||
| Net Income (TTM) | -197.88M | |||
| Net Income Avl. to Common (TTM) | -197.88M | |||
| Total Revenue Growth (Q YOY) | 45.19% | |||
| Earnings Growth (Q YOY) | 58.96% | |||
| EPS Diluted (TTM) | -1.60 | |||
| EPS Diluted Growth (Q YOY) | 60.05% | |||
| Balance Sheet | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 416.14M | |||
| Cash Per Share (Q) | $3.34 | |||
| Total Current Assets (Q) | 788.95M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 228.54M | |||
| Current Ratio (Q) | 4.253 | |||
| Book Value Per Share (Q) | $1.84 | |||
| Total Assets (Q) | 885.05M | |||
| Total Current Liabilities (Q) | 185.51M | |||
| Total Debt (Q) | 469.78M | |||
| Total Liabilities (Q) | 656.51M | |||
| Total Common Equity (Q) | 228.54M | |||
| Cash Flow | APLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -403.00K | |||
| Cash from Financing (TTM) | 149.24M | |||
| Net Change in Cash (TTM) | 60.31M | |||
| Levered Free Cash Flow (TTM) | -93.16M | |||
| Cash from Operations (TTM) | -87.87M | |||
